Certolizumab pegol is effective for chronic plaque psoriasis regardless of previous exposure to systemic therapy: A pooled subanalysis of ongoing phase 3 studies (CIMPASI-1, CIMPASI-2, and CIMPACT) - 03/08/18
Andrew Blauvelt, Oregon Medical Research Center; Kristian Reich, SCIderm Research Institute and Dermatologikum Hamburg; Mark Lebwohl, Icahn School of Medicine at Mount Sinai; Carle Paul, Paul Sabatier University; Craig Leonardi, Central Dermatology; Diamant Thaçi, University of Lubeck, Vincent Piguet, Cardiff University University Hospital of Wales, University of Toronto Women’s College Hospital; Janice Drew, Dermira, Inc., and UCB BioSciences, Inc.; Daniel Burge, Dermira, Inc., and UCB BioSciences, Inc.; Luke Peterson, Dermira, Inc., and UCB BioSciences, Inc.; Robet Rolleri, Dermira, Inc., and UCB BioSciences, Inc.; Jean-Philippe Lacour, University Hospital of Nice; Alice B. Gottlieb, New York Medical College
Le texte complet de cet article est disponible en PDF.| Commercial support: This study was funded by Dermira, Inc. Dermira and UCB are in a strategic collaboration to evaluate the efficacy and safety of certolizumab pegol in the treatment of moderate-to-severe plaque psoriasis. Medical writing support provided by Prescott Med. |
Vol 79 - N° 3S1
P. AB67 - septembre 2018 Retour au numéro
Article précédent
- Certolizumab pegol is effective for chronic plaque psoriasis across patient subgroups: A pooled subanalysis from ongoing phase 3 studies (CIMPASI-1, CIMPASI-2, and CIMPACT)
- Challenging diagnosis of rare panniculitis
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?